We chose this antibody-drug conjugate due to several concerns: (1) Efficacy: naked antibody-mediated cancer therapy requires very high surface concentration, such as Herceptin for HER2+ cancers and cirmtuzumab for ROR1 in CLL and mantle cell lymphoma. This evidence concerns the gene ERBB2 and cancer.